Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-TCR 2021 | Mechanisms of resistance to CAR T-cell therapies

John Rossi, MS, CERo Therapeutics, San Francisco, CA, discusses mechanisms of resistance and relapse in chimeric antigen receptor (CAR) T-cell therapies. T cells of patients with leukemia, lymphoma or non-Hodgkin lymphoma who have previously received multiple lines of treatment will have a lower proliferative capability and consequently have worse outcomes. Patient response to lymphodepletion therapy, as well as the tumor microenvironment can additionally determine efficacy of CAR T-cell therapies, and tumors can exhibit an immune desert phenotype during relapse, making treatment more difficult. This interview took place at the 2021 CAR-TCR Summit 2021.


John Rossi is an employee and equity stakeholder of CERo Therapeutics.